Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Maurizio Zangari to Survival Rate

This is a "connection" page, showing publications Maurizio Zangari has written about Survival Rate.

 
Connection Strength
  
 
 
0.408
  
  1. Talamo G, Rakszawski KL, Rybka WB, Dolloff NG, Malysz J, Berno T, Zangari M. Effect of time to infusion of autologous stem cells (24 vs. 48?h) after high-dose melphalan in patients with multiple myeloma. Eur J Haematol. 2012 Aug; 89(2):145-50.
    View in: PubMed
    Score: 0.087
  2. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006 Aug; 134(4):399-405.
    View in: PubMed
    Score: 0.058
  3. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):88-95.
    View in: PubMed
    Score: 0.048
  4. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun; 4(1):32-5.
    View in: PubMed
    Score: 0.046
  5. Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, Schinke C, Thanendrarajan S, Davies FE, Hoering A, Morgan GJ. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020 Jan 28; 4(2):422-431.
    View in: PubMed
    Score: 0.037
  6. Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008 Apr 15; 112(8):1754-64.
    View in: PubMed
    Score: 0.016
  7. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007 Aug 01; 110(3):827-32.
    View in: PubMed
    Score: 0.015
  8. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84.
    View in: PubMed
    Score: 0.015
  9. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 Feb 15; 109(4):1692-700.
    View in: PubMed
    Score: 0.015
  10. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 09; 354(10):1021-30.
    View in: PubMed
    Score: 0.014
  11. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003 Nov; 123(3):484-9.
    View in: PubMed
    Score: 0.012
  12. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol. 2003 Aug; 122(3):430-40.
    View in: PubMed
    Score: 0.012
  13. Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003 Jan; 120(1):44-52.
    View in: PubMed
    Score: 0.011
  14. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002 Sep; 118(4):1041-7.
    View in: PubMed
    Score: 0.011
  15. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002 Jan; 116(1):211-7.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.